.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
Dow
Healthtrust
Chubb
Mallinckrodt
Federal Trade Commission
Argus Health
Express Scripts
Merck

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,375,972

« Back to Dashboard

Which drugs does patent 6,375,972 protect, and when does it expire?


Patent 6,375,972 protects ILUVIEN and is included in one NDA.

This patent has one hundred and fifty-five patent family members in twenty-six countries.

Summary for Patent: 6,375,972

Title: Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Abstract:A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.
Inventor(s): Guo; Hong (Bellmont, MA), Ashton; Paul (Boston, MA)
Assignee: Control Delivery Systems, Inc. (Watertown, MA)
Application Number:09/558,207
Patent Claim Types:
see list of patent claims
Delivery; Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Alimera Sciences Inc
ILUVIEN
fluocinolone acetonide
IMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► SubscribeY TREATMENT OF DIABETIC MACULAR EDEMA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,375,972

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,566,336In situ gelling drug delivery system► Subscribe
7,439,249Inhibitors of phosphatases► Subscribe
8,815,284Bioerodible sustained release drug delivery systems► Subscribe
9,192,579Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof► Subscribe
8,574,659Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof► Subscribe
8,574,613Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof► Subscribe
8,871,241Injectable sustained release delivery devices► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,375,972

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan200509998► Subscribe
TaiwanI496597► Subscribe
Taiwan201422269► Subscribe
TaiwanI445559► Subscribe
Taiwan200526285► Subscribe
TaiwanI377958► Subscribe
Taiwan200514581► Subscribe
TaiwanI367103► Subscribe
Taiwan200515919► Subscribe
TaiwanI356714► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Argus Health
Mallinckrodt
Daiichi Sankyo
McKinsey
Dow
Chubb
Moodys
Queensland Health
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot